| 1 | across | 15,650 |
| 2 | accross | 4 |
| 3 | adjudicates | 2 |
| 4 | bias.all | 2 |
| 5 | matuzumab-treated | 2 |
| 6 | mid-l-name | 2 |
| 7 | -berlin-frankfurt-münster | 1 |
| 8 | /bcr-abl- | 1 |
| 9 | 1,2,4-benzotriazinyls | 1 |
| 10 | 12,727 | 1 |
| 11 | 5' | 1 |
| 12 | afraid=8 | 1 |
| 13 | analysis.included | 1 |
| 14 | appends | 1 |
| 15 | be-ween | 1 |
| 16 | beetween | 1 |
| 17 | bias.not | 1 |
| 18 | criteria.primary | 1 |
| 19 | differed.six | 1 |
| 20 | dist-raigad | 1 |
| 21 | dna-p. | 1 |
| 22 | effect.in | 1 |
| 23 | electrolyte-induced | 1 |
| 24 | encompasing | 1 |
| 25 | folfox4/folfox4-placebo | 1 |
| 26 | folfox4/folfox4-placebo/folfox4-bevacizumab | 1 |
| 27 | geographic/climate | 1 |
| 28 | important=9 | 1 |
| 29 | inbetween | 1 |
| 30 | ingaas/gaas | 1 |
| 31 | intervals-with | 1 |
| 32 | interventions.twelve | 1 |
| 33 | judgements.two | 1 |
| 34 | linguistic/cognitive | 1 |
| 35 | lyngbyacyclamide | 1 |
| 36 | non-hyperdiploid | 1 |
| 37 | ofthree | 1 |
| 38 | oftwo | 1 |
| 39 | point.for | 1 |
| 40 | reporting.for | 1 |
| 41 | studying… | 1 |
| 42 | trial-have | 1 |
| 43 | within/among | 1 |
| 44 | work-like | 1 |
| 45 | xelox/xelox-placebo | 1 |
| 46 | xelox/xelox-placebo/xelox-bevacizumab | 1 |
| 1 | -berlin-frankfurt-münster | 1 |
| 2 | /bcr-abl- | 1 |
| 3 | 1,2,4-benzotriazinyls | 1 |
| 4 | 12,727 | 1 |
| 5 | 5' | 1 |
| 6 | accross | 4 |
| 7 | across | 15,650 |
| 8 | adjudicates | 2 |
| 9 | afraid=8 | 1 |
| 10 | analysis.included | 1 |
| 11 | appends | 1 |
| 12 | be-ween | 1 |
| 13 | beetween | 1 |
| 14 | bias.all | 2 |
| 15 | bias.not | 1 |
| 16 | criteria.primary | 1 |
| 17 | differed.six | 1 |
| 18 | dist-raigad | 1 |
| 19 | dna-p. | 1 |
| 20 | effect.in | 1 |
| 21 | electrolyte-induced | 1 |
| 22 | encompasing | 1 |
| 23 | folfox4/folfox4-placebo | 1 |
| 24 | folfox4/folfox4-placebo/folfox4-bevacizumab | 1 |
| 25 | geographic/climate | 1 |
| 26 | important=9 | 1 |
| 27 | inbetween | 1 |
| 28 | ingaas/gaas | 1 |
| 29 | intervals-with | 1 |
| 30 | interventions.twelve | 1 |
| 31 | judgements.two | 1 |
| 32 | linguistic/cognitive | 1 |
| 33 | lyngbyacyclamide | 1 |
| 34 | matuzumab-treated | 2 |
| 35 | mid-l-name | 2 |
| 36 | non-hyperdiploid | 1 |
| 37 | ofthree | 1 |
| 38 | oftwo | 1 |
| 39 | point.for | 1 |
| 40 | reporting.for | 1 |
| 41 | studying… | 1 |
| 42 | trial-have | 1 |
| 43 | within/among | 1 |
| 44 | work-like | 1 |
| 45 | xelox/xelox-placebo | 1 |
| 46 | xelox/xelox-placebo/xelox-bevacizumab | 1 |
| 1 | 5' | 1 |
| 2 | /bcr-abl- | 1 |
| 3 | dna-p. | 1 |
| 4 | 12,727 | 1 |
| 5 | afraid=8 | 1 |
| 6 | important=9 | 1 |
| 7 | folfox4/folfox4-placebo/folfox4-bevacizumab | 1 |
| 8 | xelox/xelox-placebo/xelox-bevacizumab | 1 |
| 9 | dist-raigad | 1 |
| 10 | electrolyte-induced | 1 |
| 11 | analysis.included | 1 |
| 12 | matuzumab-treated | 2 |
| 13 | non-hyperdiploid | 1 |
| 14 | lyngbyacyclamide | 1 |
| 15 | ofthree | 1 |
| 16 | work-like | 1 |
| 17 | mid-l-name | 2 |
| 18 | geographic/climate | 1 |
| 19 | trial-have | 1 |
| 20 | linguistic/cognitive | 1 |
| 21 | interventions.twelve | 1 |
| 22 | encompasing | 1 |
| 23 | within/among | 1 |
| 24 | intervals-with | 1 |
| 25 | bias.all | 2 |
| 26 | be-ween | 1 |
| 27 | inbetween | 1 |
| 28 | beetween | 1 |
| 29 | effect.in | 1 |
| 30 | folfox4/folfox4-placebo | 1 |
| 31 | xelox/xelox-placebo | 1 |
| 32 | judgements.two | 1 |
| 33 | oftwo | 1 |
| 34 | -berlin-frankfurt-münster | 1 |
| 35 | reporting.for | 1 |
| 36 | point.for | 1 |
| 37 | ingaas/gaas | 1 |
| 38 | appends | 1 |
| 39 | adjudicates | 2 |
| 40 | 1,2,4-benzotriazinyls | 1 |
| 41 | across | 15,650 |
| 42 | accross | 4 |
| 43 | bias.not | 1 |
| 44 | differed.six | 1 |
| 45 | criteria.primary | 1 |
| 46 | studying… | 1 |